Trevi Therapeutics Inc

Trevi Therapeutics operates with a strong liquidity position, as evidenced by a current ratio of 19.66, indicating that the company has significantly more current assets than current liabilities. The company's cash and equivalents amount to $18.91 million, and it has no long-term debt, which further supports its liquidity profile. The price-to-book ratio of 10.81 suggests that the market is valuing the company's equity at a premium relative to its book value. The company's profitability metrics are currently negative, with a return on equity (ROE) of -23.33% and a return on assets (ROA) of -22.1%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating income and net income are both negative, at -$49.33 million and -$42.76 million, respectively, highlighting the company's ongoing financial challenges. Trevi Therapeutics does not disclose specific segment or geographic revenue data in the provided financial snapshot, making it difficult to assess the concentration of its revenue across different business lines or regions. However, the company's focus on rare diseases suggests a specialized market approach, which may limit its geographic diversification. The company's growth trajectory is not clearly defined in the provided data, as there are no specific revenue growth figures or outlooks for the current or next fiscal year. The negative operating and net income figures suggest that the company is not currently in a growth phase and may be in a development or expansion stage. The risk assessment for Trevi Therapeutics indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's capital structure, with no long-term debt and a high current ratio, supports this low liquidity risk assessment. The dilution risk is also low, as the company has not issued additional shares recently, and there are no indications of future dilution. Recent events and filings for Trevi Therapeutics do not show any significant changes or developments that would impact the company's financial position or strategic direction. The company's focus remains on the development and commercialization of its therapies, with no major new product launches or regulatory approvals reported in the provided data.